Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Savaria Corp T.SIS

Alternate Symbol(s):  SISXF

Savaria Corporation is a Canada-based company engaged in the accessibility industry. The Company provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its segments include Accessibility and Patient Care. It designs, manufactures, distributes and installs accessibility equipment, such as stairlifts for straight and curved... see more

TSX:SIS - Post Discussion

View:
Post by retiredcf on Mar 07, 2024 9:37am

TD

Have a $26.00 target. GLTA

 

Savaria Corp.

(SIS-T) C$16.80

Solid Top Line Performance Offset By Extra Savaria One Costs

 

Event

Savaria reported Q4/23 revenue of $217mm, a modest beat to TD/consensus

estimate of $214mm/$215mm. Adjusted EBITDA (including ~$2mm in Savaria

One Costs) was $33.1mm, below TD/consensus of $35.2mm/$35.5mm.

Management reaffirmed its 2025 targets of $1bln revenue and 20% adj.

EBITDA margin.
 

Impact: MIXED
 

The Accessibility segment delivered another quarter of strong top line

performance, highlighted by ~10% organic growth and a robust backlog despite

accelerated order completion. While Patient Care is an inherently lumpy business

(and up 3% in FY2023), it reported the first organic decline since Q1/21 which we

believe, together with weaker-than-expected EBITDA (mostly on higher Savaria One

costs), could lead to modest pressure on the shares today (which are up 37% from

November 2023 trough). Other highlights include:
 

Accessibility: 9.5% organic revenue growth (TD est: 6.5% including forex)

driven by strong demand across residential and commercial sectors, pricing, and

cross-selling synergies with Handicare. Despite improving lead times (especially

in Europe), robust demand stemming from new construction projects in North

America supported a robust backlog. Better cost absorption from higher volume

and price increases drove an ~25bps expansion y/y in adjusted EBITDA margin

(albeit < 120bps TD est.).
 

Patient Care: 5.9% organic revenue decline (TD est: 4.0% growth including

forex) given the uncertain timing of orders, reduced year-end government

spending and the lapping of a very tough (i.e. ~26% two-year stacked growth).

That said, the backlog remains healthy and despite the top line decline, adjusted

EBITDA margin expanded by a substantial ~300bps (> 250bps TD est) owing

to better mix and pricing.
 

Strong balance sheet with ample liquidity: Leverage fell to 2.07x (down from

2.28x in Q3/23), with ~$223mm available in cash and credit facilities.
 

Divestiture of Adapted Vehicle manufacturing businesses. Post-quarter,

Savaria closed the sale of Van-Action and Freedom Motors on February 1, 2024.

We estimate that the two businesses represent ~$22mm of annualized revenue.
 

The conference call is at 8:30 a.m. today (which can be accessed here). We will

look for more colour around the underlying demand trends for Patient Care, and any

initial progress under the Savaria One initiative.

 
Be the first to comment on this post